Irbesartan Hctz Fair-Med (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptors, preventing the hormone from causing blood‑vessel constriction and aldosterone‑driven sodium retention. This results in vasodilation and reduced fluid volume, which together lower systemic blood pressure.

The appropriate dose of Irbesartan Hctz Fair-Med is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Safety of Irbesartan Hctz Fair-Med in pregnancy and lactation has not been established. Because angiotensin‑II receptor blockers may cause fetal harm, the product is generally avoided during pregnancy. Breastfeeding mothers should consult their physician, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with monotherapy agents, the Irbesartan/HCTZ combination offers dual mechanisms—vasodilation from irbesartan and diuresis from hydrochlorothiazide—allowing better blood‑pressure control in patients who need more than one drug class. It can reduce pill burden versus taking separate agents, but clinicians must monitor for additive side effects such as electrolyte changes.

Store the tablets at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Irbesartan Hctz Fair-Med is taken orally, usually once daily, with a full glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Swallow the tablet whole; do not crush or chew it.

Serious risks include severe dehydration, acute kidney injury, hyperkalemia (especially when combined with potassium‑sparing agents), and rare allergic reactions such as anaphylaxis. Patients should report symptoms like sudden weakness, swelling, difficulty breathing, or a marked drop in urine output to their healthcare provider promptly.

The medication is contraindicated in patients with severe renal impairment, hyperkalemia, known hypersensitivity to irbesartan or hydrochlorothiazide, and in women who are pregnant. Caution is also advised for individuals with hepatic disease, severe dehydration, or those taking interacting medications listed under major interactions.